GlassScriptPhysician profile
Jordan C Smith
NPI 1013514553
$12,381.67
in general payments reported to CMS, 2019-2025
26 companies · $3,027 in 2025
The $3,027 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,327 · 2022: $2,593 · 2023: $2,790 · 2024: $2,646 · 2025: $3,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,418 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,417.51 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,886.44 | 2021-2025 | |
| Amgen INC. | $2,299.70 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $1,359.39 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,236.53 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $726.76 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $485.41 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $462.42 | 2022-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.43 | 2022-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $390.07 | 2022-2025 | Acthar |
| Genentech USA, INC. | $382.09 | 2021-2025 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $353.25 | 2024-2025 | Orencia |
| Lilly USA, LLC | $273.51 | 2021-2025 | Taltz, Zepbound |
| Pfizer INC. | $259.84 | 2021-2025 | |
| Sobi, INC | $181.57 | 2022-2024 | |
| Aurinia Pharma U.S., INC. | $123.84 | 2022-2023 | Lupkynis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $97.13 | 2023-2025 | Idacio |
| Radius Health, INC. | $92.46 | 2023-2024 | Tymlos |
| Ani Pharmaceuticals, INC. | $88.95 | 2022-2025 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $61.47 | 2023-2024 | Truxima |
| Invivyd INC | $40.15 | 2025 | Pemgarda |
| Horizon Therapeutics Plc | $39.39 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $37.50 | 2022-2023 | Opsumit, Uptravi |
| Genzyme Corporation | $33.49 | 2021 | |
| Ferring Pharmaceuticals INC. | $27.93 | 2024 | Euflexxa |
| Alexion Pharmaceuticals, INC. | $24.60 | 2024 | Strensiq |
| Tersera Therapeutics LLC | $16.35 | 2023 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.